AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Urinary retention is a common condition in men characterised by the inability to fully empty the bladder despite the urge to ...

MARCH is prostate cancer awareness month and a service for patients with urological cancers – including prostate cancer, ...

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more effective model for predicting ...

Aura Biosciences (AURA) has reported its Q4 and full-year 2024 financial results, prompting an ongoing decline in shares ...